Answers are grounded in this paper and cite their sources.
Dual GIP/GLP-1 receptor agonists promote substantial weight loss, predominantly through reductions in fat mass, but may also reduce lean mass. Following treatment discontinuation, clinical studies indicate progressive weight regain and attenuation of some cardiometabolic benefits. However, the body composition of regained weight remains poorly characterized, and available data do not establish whether the lost body compartments are restored in the same proportions. This review discusses body composition trajectories during weight loss and after withdrawal of tirzepatide, together with the role of nutritional interventions and exercise in preserving lean mass. The literature reviewed highlights the importance of individualized nutritional care, with particular attention to protein adequacy and nutrient density, combined with exercise, especially resistance training. These strategies may support the preservation of muscle mass and function, although evidence specifically addressing their effectiveness in maintaining body composition after tirzepatide withdrawal remains limited. Management should therefore be continuous and multidisciplinary, and further studies are needed to assess weight, body composition and neuromuscular function together throughout treatment and following discontinuation.
No takes yet. Share an insight, caveat, or question.
Kyria Jayanne Clímaco Cruz (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: